Hypothesis

Senescent endothelial cells act as transient mitochondrial donors, releasing exosomes that bolster neighboring cell bioenergetics and preserve capillary integrity during acute tissue injury. Premature senolytic ablation removes this rescue mechanism, exacerbating ischemia‑reperfusion injury and driving maladaptive fibrosis.

Mechanistic premise

• During wound healing, a subpopulation of endothelial cells undergoes p21‑dependent senescence after VEGF‑driven proliferation (see 8).
• These senescent endothelial cells upregulate mitochondrial biogenesis genes (e.g., TFAM, NRF1) and load functional mitochondria into CD63⁺ exosomes via the Rab27a‑dependent secretory pathway (hypothesized extension of 1 and 4).
• Exosomal mitochondria are taken up by adjacent endothelial progenitors and stromal cells, boosting ATP production, reducing ROS, and promoting VEGF‑mediated angiogenic sprouting (paralleling the acute SASP‑immune recruitment described in 4).
• This mitochondrial transfer is time‑restricted: senescent cells retain the phenotype for ~48 h before switching to a pro‑fibrotic SASP (as shown in chronic liver models 7).

Predictions

1. In murine full‑thickness skin wounds, inhibition of exosome release (GW4869) or mitochondrial loading (TFAM siRNA) in senescent endothelial cells will delay closure and increase collagen deposition, phenocopying early senolytic treatment.
2. Administering isolated senescent‑cell‑derived exosomes to senolytic‑treated wounds will rescue angiogenic density and reduce fibrosis, even when senescent cells are cleared.
3. Persistent senescent endothelial cells beyond 72 h will shift exosome cargo toward miR‑21 and TGF‑β1, correlating with maladaptive remodeling (testable via small‑RNA sequencing of exosomes).

Experimental approach

• Use inducible p21‑CreERT2;Rosa26‑LSL‑tdTomato mice to label senescent endothelial cells post‑injury.
• Isolate tdTomato⁺ exosomes at 24 h and 72 h post‑wound; assess mitochondrial content by Mitotracker fluorescence and ATP assays.
• Treat wounds with senolytic (navitoclax) at 12 h or 60 h; compare exosome microvesicle levels, capillary perfusion (Laser Doppler), and hydroxyproline content.
• Rescue experiments: inject purified 24 h exosomes into navitoclax‑treated wounds at 24 h.

Potential pitfalls & controls

• Off‑target effects of GW4869; use siRNA against Rab27a as alternative.
• Exosome heterogeneity; employ size‑exclusion chromatography and CD63⁺ tdTomato⁺ gating.
• Compensatory senescence in other lineages; include endothelial‑specific p16‑CreERT2 line to verify specificity.

If the hypothesis holds, it reframes senescent cells not merely as signal sources but as dynamic bioenergetic chaperones whose timely removal is detrimental, urging a window‑based senolytic strategy rather than blanket clearance.